Literature DB >> 16282215

The interpretation of random-effects meta-analysis in decision models.

A E Ades1, G Lu, J P T Higgins.   

Abstract

This article shows that the interpretation of the random-effects models used in meta-analysis to summarize heterogeneous treatment effects can have a marked effect on the results from decision models. Sources of variation in meta-analysis include the following: random variation in outcome definition (amounting to a form of measurement error), variation between the patient groups in different trials, variation between protocols, and variation in the way a given protocol is implemented. Each of these alternatives leads to a different model for how the heterogeneity in the effect sizes previously observed might relate to the effect size(s) in a future implementation. Furthermore, these alternative models require different computations and, when the net benefits are nonlinear in the efficacy parameters, result in different expected net benefits. The authors' analysis suggests that the mean treatment effect from a random-effects meta-analysis will only seldom be an appropriate representation of the efficacy expected in a future implementation. Instead, modelers should consider either the predictive distribution of a future treatment effect, or they should assume that the future implementation will result in a distribution of treatment effects. A worked example, in a probabilistic, Bayesian posterior framework, is used to illustrate the alternative computations and to show how parameter uncertainty can be combined with variation between individuals and heterogeneity in meta-analysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282215     DOI: 10.1177/0272989X05282643

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  300 in total

Review 1.  The Prognostic and Predictive Value of Dihydropyrimidine Dehydrogenase-Related Indicators in Clinical Outcomes of Chemotherapy in Colorectal Cancer Patients: a Systematic Review and Meta-Analysis.

Authors:  Xiaojun Sun; Shilei Guo
Journal:  Pathol Oncol Res       Date:  2018-12-05       Impact factor: 3.201

2.  When to wait for more evidence? Real options analysis in proton therapy.

Authors:  Janneke P C Grutters; Keith R Abrams; Dirk de Ruysscher; Madelon Pijls-Johannesma; Hans J M Peters; Eric Beutner; Philippe Lambin; Manuela A Joore
Journal:  Oncologist       Date:  2011-12-06

3.  No head-to-head trial? simulate the missing arms.

Authors:  J Jaime Caro; K Jack Ishak
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  XPC Lys939Gln and Ala499Val polymorphisms in colorectal cancer susceptibility: a meta-analysis of case-control studies.

Authors:  Chuan Liu; Qinghua Yin; Mingzhen Ying; Junhui Lin; Lian Li; Guangjun Jiao; Mei Wang; Yajie Wang
Journal:  Mol Biol Rep       Date:  2014-01-03       Impact factor: 2.316

5.  The APE1 Asp148Glu polymorphism and colorectal cancer susceptibility: a meta-analysis.

Authors:  Erdong Shen; Chuan Liu; Li Wei; Jianbing Hu; Jie Weng; Qinghua Yin; Yajie Wang
Journal:  Tumour Biol       Date:  2013-11-20

Review 6.  Quantitative assessment of the association between XPG Asp1104His polymorphism and bladder cancer risk.

Authors:  Chuan Liu; Qinghua Yin; Jianbing Hu; Jie Weng; Yajie Wang
Journal:  Tumour Biol       Date:  2013-09-06

Review 7.  Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis.

Authors:  E G Wilmot; C L Edwardson; F A Achana; M J Davies; T Gorely; L J Gray; K Khunti; T Yates; S J H Biddle
Journal:  Diabetologia       Date:  2012-08-14       Impact factor: 10.122

8.  Human papillomavirus is not associated with colorectal cancer in a large international study.

Authors:  Michele C Gornick; Xavier Castellsague; Gloria Sanchez; Thomas J Giordano; Michelle Vinco; Joel K Greenson; Gabriel Capella; Leon Raskin; Gad Rennert; Stephen B Gruber; Victor Moreno
Journal:  Cancer Causes Control       Date:  2010-01-20       Impact factor: 2.506

9.  Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Mingming Liang; Yun Zhang; Chenyu Sun; Feras Kamel Rizeq; Min Min; Tingting Shi; Yehuan Sun
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

10.  Methylenetetrahydrofolate reductase (MTHFR) polymorphism susceptibility to schizophrenia and bipolar disorder: an updated meta-analysis.

Authors:  Cai-Yun Hu; Zhen-Zhong Qian; Feng-Feng Gong; Shan-Shan Lu; Fang Feng; Yi-Le Wu; Hui-Yun Yang; Ye-Huan Sun
Journal:  J Neural Transm (Vienna)       Date:  2014-06-18       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.